Clostridium Difficile Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Study of GlaxoSmithKline's (GSK) Clostridium Difficile Vaccine to Investigate the Safety and Ability to Provoke an Immune Response in the Body When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years
Condition: Clostridium Infections Interventions: Biological: C. difficile investigational vaccine based on the F2 antigen (GSK2904545A); Biological: C. difficile investigational vaccine based on the F2 antigen (GSK2904545A) adjuvanted with AS01B; Drug: Placebo Sponsor: GlaxoSmithKline Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2019 Category: Research Source Type: clinical trials
Protocol for Admission Toxigenic C. Difficile Surveillance
Condition: Clostridium Difficile Infection Intervention: Other: Standard Practice to Prevent Hospital Onset CDI Sponsor: NorthShore University HealthSystem Research Institute Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 10, 2019 Category: Research Source Type: clinical trials
